Chapter 13 : Pertussis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Pertussis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815592/9781555814441_Chap13-1.gif /docserver/preview/fulltext/10.1128/9781555815592/9781555814441_Chap13-2.gif


Compared to the prevaccination era, reported cases of pertussis declined by 92.2% and pertussis deaths by 99.3%. The proportion of reported pertussis cases that were confirmed by PCR in the National Notifiable Diseases Surveillance System increased from 12% in 1997 to 44% in 2005. The organism produces a number of biologically active virulence factors that play different roles in the course of the disease. Well-characterized, standardized single-point serologic assays that distinguish between the immune response from clinical pertussis and vaccine-mediated immunity would provide useful adjuncts to pertussis diagnosis and surveillance. Early treatment of pertussis with recommended antimicrobials may ameliorate the severity and reduce the duration of clinical symptoms, eliminate from the nasopharynx, shorten the period of infectivity, and therefore reduce the risk of secondary spread to susceptible individuals. The recommended antimicrobial agents and dosing regimens for postexposure prophylaxis are the same as those for treatment of pertussis. Acellular vaccines contain inactivated pertussis toxoid and one or more of four other purified antigens (FHA, PRN, FIM2, and FIM3) derived from . A major priority for public health is the development of reliable standardized laboratory tests that are rapid and have high sensitivity and specificity early in the course of pertussis disease. Successful implementation of recommendations for newly licensed adolescent and adult pertussis vaccines should reduce the current disease burden and result in changes in the epidemiology and clinical spectrum of the disease.

Citation: Tiwari T. 2008. Pertussis, p 257-275. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch13

Key Concept Ranking

Bacterial Respiratory Diseases
Adenylate Cyclase Toxin
Enzyme-Linked Immunosorbent Assay
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1.
Figure 1.

Pertussis global annual reported incidence and diphtheria-tetanus-pertussis vaccine coverage with three doses, 1980 to 2006. Reproduced from the WHO 2006 global summary ( ).

Citation: Tiwari T. 2008. Pertussis, p 257-275. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch13
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Cases of pertussis, United States, 1922 to 2006, as reported to the National Notifiable Disease Surveillance System of the Centers for Disease Control and Prevention.

Citation: Tiwari T. 2008. Pertussis, p 257-275. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch13
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Anonymous. 2005. Pertussis in Newfoundland and Labrador: 1991–2004. Can. Commun. Dis. Rep. 31:235237.
2. Aoyama, T.,, K. Sunakawa,, S. Iwata,, Y. Takeuchi,, and R. Fujii. 1996. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J. Pediatr. 129:761764.
3. Bace, A.,, T. Zrnic,, J. Begovac,, N. Kuzmanovic,, and J. Culig. 1999. Short-term treatment of pertussis with azithromycin in infants and young children. Eur. J. Clin. Microbiol. Infect. Dis. 18:296298.
4. Bartkus, J. M.,, B. A. Juni,, K. Ehresmann,, C. A. Miller,, G. N. Sanden,, P. K. Cassiday,, M. Saubolle,, B. Lee,, J. Long,, A. R. Harrison, Jr.,, and J. M. Besser. 2003. Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. J. Clin. Microbiol. 41:11671172.
5. Bass, J. W.,, and R. R. Wittler. 1994. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J. 13:343345.
6. Bassinet, L.,, P. Gueirard,, B. Maitre,, B. Housset,, P. Gounon,, and N. Guiso. 2000. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect. Immun. 68:19341941.
7. Baughman, A. L.,, K. M. Bisgard,, K. M. Edwards,, D. Guris,, M. D. Decker,, K. Holland,, B. D. Meade,, and F. Lynn. 2004. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab. Immunol. 11:10451053.
8. Bauwens, J. E.,, D. H. Spach,, T. W. Schacker,, M. M. Mustafa,, and R. A. Bowden. 1992. Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J. Clin. Microbiol. 30:24742475.
9. Bejuk, D.,, J. Begovac,, A. Bace,, N. Kuzmanovic-Sterk,, and B. Aleraj. 1995. Culture of Bordetella pertussis from three upper respiratory tract specimens. Pediatr. Infect. Dis. J. 14:6465.
10. Bergfors, E.,, B. Trollfors,, J. Taranger,, T. Lagergard,, V. Sundh,, and G. Zackrisson. 1999. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int. J. Infect. Dis. 3:140146.
11. Bisgard, K. M.,, F. B. Pascual,, K. R. Ehresmann,, C. A. Miller,, C. Cianfrini,, C. E. Jennings,, C. A. Rebmann,, J. Gabel,, S. L. Schauer,, and S. M. Lett. 2004. Infant pertussis: who was the source? Pediatr. Infect. Dis. J. 23:985989.
12. Broder, K. R.,, M. M. Cortese,, J. K. Iskander,, K. Kretsinger,, B. A. Slade,, K. H. Brown,, C. M. Mijalski,, T. Tiwari,, E. J. Weston,, A. C. Cohn,, P. U. Srivastava,, J. S. Moran,, B. Schwartz,, and T. V. Murphy. 2006. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. Recomm. Rep. 55(RR-3):134.
13. Caro, V.,, E. Njamkepo,, S. C. Van Amersfoorth,, F. R. Mooi,, A. Advani,, H. O. Hallander,, Q. He,, J. Mertsola,, M. Riffelmann,, C. Vahrenholz,, C. H. von Konig,, and N. Guiso. 2005. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect. 7:976982.
14. Caro, V.,, V. Bouchez,, N. Guiso,, B. Gatti,, M. R. Agosti,, and S. E. Ayala. 2007. Pertussis in Argentina and France. Vaccine 25:43354339.
15. Cassiday, P.,, G. Sanden,, K. Heuvelman,, F. Mooi,, K. M. Bisgard,, and T. Popovic. 2000. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935–1999. J. Infect. Dis. 182:14021408.
16. Cattaneo, L. A.,, G. W. Reed,, D. H. Haase,, M. J. Wills,, and K. M. Edwards. 1996. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J. Infect. Dis. 173:12561259.
17. Centers for Disease Control and Prevention. 2007. Outbreaks of respiratory illness mistakenly attributed to pertussis—New Hampshire, Massachusetts, and Tennessee, 2004–2006. Morb. Mortal. Wkly. Rep. 56:838841.
18. Centers for Disease Control and Prevention. 2007. National vaccination coverage among adolescents aged 13–17 years—United States, 2006. Morb. Mortal. Wkly. Rep. 56:885888.
19. Centers for Disease Control and Prevention. 2008. Recommended immunization schedules for person aged 0–18 years—United States. Morb. Mortal. Wkly. Rep. 56(51–52):Q1Q4.
20. Cherry, J. D. 2007. Immunity to pertussis. Clin. Infect. Dis. 44:12781279.
21. Cloud, J. L.,, W. Hymas,, and K. C. Carroll. 2002. Impact of nasopharyngeal swab types on detection of Bordetella pertussis by PCR and culture. J. Clin. Microbiol. 40:38383840.
22. Council of State and Territorial Epidemiologists. 1997. CSTE position statement 1997-ID-9: public health surveillance, control and prevention of pertussis. Council of State and Territorial Epidemiologists, Atlanta, GA.
23. Crowcroft, N. S.,, N. Andrews,, C. Rooney,, M. Brisson,, and E. Miller. 2002. Deaths from pertussis are underestimated in England. Arch. Dis. Child. 86:336338.
24. Crowcroft, N. S.,, R. Booy,, T. Harrison,, L. Spicer,, J. Britto,, Q. Mok,, P. Heath,, I. Murdoch,, M. Zambon,, R. George,, and E. Miller. 2003. Severe and unrecognised: pertussis in UK infants. Arch. Dis. Child. 88:802806.
25. De Melker, H. E.,, J. F. Schellekens,, S. E. Neppelenbroek,, F. R. Mooi,, H. C. Rumke,, and M. A. Conynvan Spaendonck. 2000. Reemergence of pertussis in the highly vaccinated population of The Netherlands: observations on surveillance data. Emerg. Infect. Dis. 6:348357.
26. De Schutter, I.,, A. Malfroot,, I. Dab,, N. Hoebrekx,, G. Muyldermans,, and D. Pierard. 2003. Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members. Clin. Infect. Dis. 36:13911396.
27. De Serres, G.,, R. Shadmani,, B. Duval,, N. Boulianne,, P. Dery,, F. M. Douville,, L. Rochette,, and S. A. Halperin. 2000. Morbidity of pertussis in adolescents and adults. J. Infect. Dis. 182:174179.
28. Edwards, K. M.,, and M. D. Decker. 2005. Pertussis vaccine, p. 471–528. In S. A. Plotkin and, W. A. Orenstein (ed.), Vaccines, 4th ed. W. B. Saunders, Philadelphia, PA.
29. Eldering, G.,, and P. Kendrick. 1938. Bacillus parapertussis: a species resembling both Bacillus pertussis and Bacillus bronchiseptica but identical with neither. J. Bacteriol. 35:561572.
30. Ewanowich, C. A.,, L. W. Chui,, M. G. Paranchych,, M. S. Peppler,, R. G. Marusyk,, and W. L. Albritton. 1993. Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology. J. Clin. Microbiol. 31:17151725.
31. Farizo, K. M.,, S. L. Cochi,, E. R. Zell,, E. W. Brink,, S. G. Wassilak,, and P. A. Patriarca. 1992. Epidemiological features of pertussis in the United States, 1980–1989. Clin. Infect. Dis. 14:708719.
32. Ferry, N. S. 1911. The etiology of canine distemper. J. Infect. Dis. 8:399420.
33. Fry, N. K.,, S. Neal,, T. G. Harrison,, E. Miller,, R. Matthews,, and R. C. George. 2001. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69:55205528.
34. Glare, E. M.,, J. C. Paton,, R. R. Premier,, A. J. Lawrence,, and I. T. Nisbet. 1990. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J. Clin. Microbiol. 28:19821987.
35. Grimpel, E.,, P. Begue,, Í. Anjak,, F. Betsou,, and N. Guiso. 1993. Comparison of polymerase chain reaction, culture, and Western immunoblot serology for diagnosis of Bordetella infection. J. Clin. Microbiol. 31:27452750.
36. Grimpel, E.,, E. Njamkepo,, P. Begue,, and N. Guiso. 1997. Rapid diagnosis of pertussis in young infants: comparison of culture, PCR, infant’s and mother’s serology. Clin. Diagn. Lab. Immunol. 4:723726.
37. Gueirard, P.,, C. Weber,, A. Le Coustumier,, and N. Guiso. 1995. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J. Clin. Microbiol. 33:20022006.
38. Guiso, N.,, C. Boursaux-Eude,, C. Weber,, S. Z. Hausman,, H. Sato,, M. Iwaki,, K. Kamachi,, T. Konda,, and D. L. Burns. 2001. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 19:32483252.
39. Guris, D.,, P. M. Strebel,, B. Bardenheier,, M. Brennan,, R. Tachdjian,, E. Finch,, M. Wharton,, and J. R. Livengood. 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin. Infect. Dis. 28:12301237.
40. Gzyl, A.,, E. Augustynowicz,, G. Gniadek,, D. Rabczenko,, G. Dulny,, and J. Slusarczyk. 2004. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 22:21222128.
41. Hallander, H. O.,, E. Reizenstein,, B. Renemar,, G. Rasmuson,, L. Mardin,, and P. Olin. 1993. Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella pertussis. J. Clin. Microbiol. 31:5052.
42. Hallander, H. O. 1999. Microbiological and serological diagnosis of pertussis. Clin. Infect. Dis. 28(Suppl. 2):S99S106.
43. Halperin, S. A.,, R. Bortolussi,, and A. J. Wort. 1989. Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. J. Clin. Microbiol. 27:752757.
44. Halperin, S. A.,, H. D. Davies,, L. Barreto,, R. Guasparini,, W. Meekison,, G. Humphreys,, and B. J. Eastwood. 1997. Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J. Pediatr. 130:525531.
45. Halperin, S. A.,, E. E. Wang,, B. Law,, E. Mills,, R. Morris,, P. Dery,, M. Lebel,, N. MacDonald,, T. Jadavji,, W. Vaudry,, D. Scheifele,, G. Delage,, and P. Duclos. 1999. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin. Infect. Dis. 28:12381243.
46. Halperin, S. A. 2007. The control of pertussis—2007 and beyond. N. Engl. J. Med. 356:110113.
47. He, Q.,, J. Mertsola,, J. P. Himanen,, O. Ruuskanen,, and M. K. Viljanen. 1993. Evaluation of pooled and individual components of Bordetella pertussis as antigens in an enzyme immunoassay for diagnosis of pertussis. Eur. J. Clin. Microbiol. Infect. Dis. 12:690695.
48. Heininger, U.,, K. Stehr,, G. Schmidt-Schlapfer,, R. Penning,, R. Vock,, W. Kleemann,, and J. D. Cherry. 1996. Bordetella pertussis infections and sudden unexpected deaths in children. Eur. J. Pediatr. 155:551553.
49. Heininger, U.,, K. Klich,, K. Stehr,, and J. D. Cherry. 1997. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 100:E10.
50. Heininger, U.,, G. Schmidt-Schlapfer,, J. D. Cherry,, and K. Stehr. 2000. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 105:E31.
51. Henry, R.,, D. Dorman,, J. Skinner,, and C. Mellis. 1981. Limitations of erythromycin in whooping cough. Med. J. Aust. 2:108109.
52. Hill, B. C.,, C. N. Baker,, and F. C. Tenover. 2000. A simplified method for testing Bordetella pertussis for resistance to erythromycin and other antimicrobial agents. J. Clin. Microbiol. 38:11511155.
53. Hoppe, J. E.,, and J. Schwaderer. 1989. Direct plating versus use of transport medium for detection of Bordetella species from nasopharyngeal swabs. Eur. J. Clin. Microbiol. Infect. Dis. 8:264265.
54. Janda, W. M.,, E. Santos,, J. Stevens,, D. Celig,, L. Terrile,, and P. C. Schreckenberger. 1994. Unexpected isolation of Bordetella pertussis from a blood culture. J. Clin. Microbiol. 32:28512853.
55. Jenkinson, D. 1988. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br. Med. J. Clin. Res. 296:612614.
56. Kandola, K.,, A. Lea,, and M. Santos. 2004. Pertussis rates in Northwest Territories after introducing adult formulation acellular vaccine (abstract). Can. J. Infect. Dis. Med. Microbiol. 15:351.
57. Kontor, E. J.,, R. J. Wegrzyn,, and R. A. Goodnow. 1981. Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchioseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). Am. J. Vet. Res. 42:16941698.
58. Korgenski, E. K.,, and J. A. Daly. 1997. Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J. Clin. Microbiol. 35:29892991.
59. Kosters, K.,, W. Riffelmann,, and C. H. Wirsing von Konig. 2001. Evaluation of a real time PCR assay for the detection of Bordetella pertussis and B. parapertussis in clinical samples. J. Med. Microbiol. 50:436440.
60. Kretsinger, K.,, K. R. Broder,, M. M. Cortese,, M. P. Joyce,, I. Ortega-Sanchez,, G. M. Lee,, T. Tiwari,, A. C. Cohn,, B. A. Slade,, J. K. Iskander,, C. M. Mijalski,, K. H. Brown,, and T. V. Murphy. 2006. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. Morb. Mortal. Wkly. Rep. Recomm. Rep. 55(RR-17):137.
61. Kwantes, W.,, D. H. Joynson,, and W. O. Williams. 1983. Bordetella pertussis isolation in general practice: 1977–79 whooping cough epidemic in West Glamorgan. J. Hyg. 90:149158.
62. Lambert, H. J. 1965. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 80:365369.
63. Langley, J. M.,, S. A. Halperin,, F. D. Boucher,, and B. Smith. 2004. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 114:e96e101.
64. Lebel, M. H.,, and S. Mehra. 2001. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr. Infect. Dis. J. 20:11491154.
65. Lee, B. 2000. Progressive respiratory distress in an infant treated for presumed pertussis. Pediatr. Infect. Dis. J. 19:475, 492493.
66. Lewis, K.,, M. A. Saubolle,, F. C. Tenover,, M. F. Rudinsky,, S. D. Barbour,, and J. D. Cherry. 1995. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr. Infect. Dis. J. 14:388391.
67. Lievano, F. A.,, M. A. Reynolds,, A. L. Waring,, J. Ackelsberg,, K. M. Bisgard,, G. N. Sanden,, D. Guris,, A. Golaz,, D. J. Bopp,, R. J. Limberger,, and P. F. Smith. 2002. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J. Clin. Microbiol. 40:28012805.
68. Lin, Y. C.,, S. M. Yao,, J. J. Yan,, Y. Y. Chen,, C. S. Chiang,, H. S. Wu,, and S. Y. Li. 2007. Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J. Med. Microbiol. 56:533537.
69. Locht, C.,, R. Antoine,, and F. Jacob-Dubuisson. 2001. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr. Opin. Microbiol. 4:8289.
70. Loeffelholz, M. J.,, C. J. Thompson,, K. S. Long,, and M. J. Gilchrist. 1999. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J. Clin. Microbiol. 37:28722876.
71. Magyar, T.,, N. Chanter,, A. J. Lax,, J. M. Rutter,, and G. A. Hall. 1988. The pathogenesis of turbinate atrophy in pigs caused by Bordetella bronchiseptica. Vet. Microbiol. 18:135146.
72. Marchant, C. D.,, A. M. Loughlin,, S. M. Lett,, C. W. Todd,, L. H. Wetterlow,, R. Bicchieri,, S. Higham,, P. Etkind,, E. Silva,, and G. R. Siber. 1994. Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. J. Infect. Dis. 169:12971305.
73. Mastrantonio, P.,, P. Spigaglia,, H. van Oirschot,, H. G. van der Heide,, K. Heuvelman,, P. Stefanelli,, and F. R. Mooi. 1999. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 145:20692075.
74. Mattoo, S.,, and J. D. Cherry. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18:326382.
75. Mazengia, E.,, E. A. Silva,, J. A. Peppe,, R. Timperi,, and H. George. 2000. Recovery of Bordetella holmesii from patients with pertussis-like symptoms: use of pulsed-field gel electrophoresis to characterize circulating strains. J. Clin. Microbiol. 38:23302333.
76. Meade, B. D.,, and A. Bollen. 1994. Recommendations for use of the polymerase chain reaction in the diagnosis of Bordetella pertussis infections. J. Med. Microbiol. 41:5155.
77. Mooi, F. R.,, Q. He,, H. van Oirschot,, and J. Mertsola. 1999. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 67:31333134.
78. Mooi, F. R.,, H. Hallander,, C. H. Wirsing von Konig,, B. Hoet,, and N. Guiso. 2000. Epidemiological typing of Bordetella pertussis isolates: recommendations for standards methodology. Eur. J. Clin. Microbiol. 19:174181.
79. Mooi, F. R.,, I. H. Van Loo,, and A. J. King. 2001. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg. Infect. Dis. 7:526528.
80. Ner, Z.,, L. A. Ross,, M. V. Horn,, T. G. Keens,, E. F. MacLaughlin,, V. A. Starnes,, and M. S. Woo. 2003. Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr. Transplant. 7:413417.
81. Pichichero, M. E.,, W. J. Hoeger,, and J. R. Casey. 2003. Azithromycin for the treatment of pertussis. Pediatr. Infect. Dis. J. 22:847849.
82. Porter, J. F.,, K. Connor,, and W. Donacchie. 1994. Isolation and characterization of Bordetella pertussis-like bacteria from ovine lungs. Microbiology 140:255.
83. Postels-Multani, S.,, H. J. Schmitt,, C. H. Wirsing von Konig,, H. L. Bock,, and H. Bogaerts. 1995. Symptoms and complications of pertussis in adults. Infection 23:139142.
84. Poynten, M.,, P. B. McIntyre,, F. R. Mooi,, K. J. Heuvelman,, and G. L. Gilbert. 2004. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect. 132:185193.
85. Qin, X.,, E. Galanakis,, E. T. Martin,, and J. A. Englund. 2007. Multitarget PCR for diagnosis of pertussis and its clinical implications. J. Clin. Microbiol. 45:506511.
86. Regan, J.,, and F. Lowe. 1977. Enrichment medium for the isolation of Bordetella. J. Clin. Microbiol. 26:13731377.
87. Register, K. B.,, and T. L. Nicholson. 2007. Misidentification of Bordetella bronchiseptica as Bordetella pertussis using a newly described real-time PCR targeting the pertactin gene. J. Med. Microbiol. 56:16081610.
88. Riffelmann, M.,, C. H. Wirsing von Konig,, V. Caro,, N. Guiso, et al. 2005. Nucleic acid amplification tests for diagnosis of Bordetella infections. J. Clin. Microbiol. 43:49254929.
89. Roush, S. W.,, T. V. Murphy, et al. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:21552163.
90. Schmitt-Grohe, S.,, J. D. Cherry,, U. Heininger,, M. A. Uberall,, E. Pineda,, and K. Stehr. 1995. Pertussis in German adults. Clin. Infect. Dis. 21:860866.
91. Senzilet, L. D.,, S. A. Halperin,, J. S. Spika,, M. Alagaratnam,, A. Morris,, and B. Smith. 2001. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis. 32:16911697.
92. Sotir, M. J.,, D. L. Cappozzo,, D. M. Warshauer,, C. E. Schmidt,, T. A. Monson,, J. L. Berg,, J. A. Zastrow,, G. W. Gabor,, and J. P. Davis. 2007. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin. Infect. Dis. 44:12161219.
93. Storsaeter, J.,, H. O. Hallander,, L. Gustafsson,, and P. Olin. 2003. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21:35423549.
94. Strebel, P. M.,, S. L. Cochi,, K. M. Farizo,, B. J. Payne,, S. D. Hanauer,, and A. L. Baughman. 1993. Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. Clin. Infect. Dis. 16:276285.
95. Tanaka, M.,, C. R. Vitek,, F. B. Pascual,, K. M. Bisgard,, J. E. Tate,, and T. V. Murphy. 2003. Trends in pertussis among infants in the United States, 1980–1999. JAMA 290:29682975.
96. Templeton, K. E.,, S. A. Scheltinga,, A. van der Zee,, B. M. Diederen,, A. M. van Kruijssen,, H. Goossens,, E. Kuijper,, and E. C. Claas. 2003. Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J. Clin. Microbiol. 41:41214126.
97. Tiwari, T.,, T. V. Murphy,, and J. Moran. 2005. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. Morb. Mortal. Wkly. Rep. Recomm. Rep. 54:116.
98. Vitek, C. R.,, F. B. Pascual,, A. L. Baughman,, and T. V. Murphy. 2003. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr. Infect. Dis. J. 22:628634.
99. Wendelboe, A. M.,, and A. Van Rie. 2006. Diagnosis of pertussis: a historical review and recent developments. Expert Rev. Mol. Diagn. 6:857864.
100. Wendelboe, A. M.,, E. Njamkepo,, A. Bourillon,, D. D. Floret,, J. Gaudelus,, M. Gerber,, E. Grimprel,, D. Greenberg,, S. Halperin,, J. Liese,, F. Munoz-Rivas,, R. Teyssou,, N. Guiso,, A. Van Rie, et al. 2007. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26:293299.
101. Wilson, K. E.,, P. K. Cassiday,, T. Popovic,, and G. N. Sanden. 2002. Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J. Clin. Microbiol. 40:29422944.
102. Wirsing von Konig, C. H.,, J. E. Hoppe,, A. Tacken,, and H. Finger. 1990. Detection of Bordetella pertussis in clinical specimens, p. 315–320. In C. R. Manclark (ed.), Proc. 6th Int. Symp. Pertussis. DHHS no. (FDA)90–1164. U.S. Public Health Service, Bethesda, MD.
103. Wirsing von Konig, C. H. 2005. Use of antibiotics in the prevention and treatment of pertussis. Pediatr. Infect. Dis. J. 24:S66S68.
104. Woolfrey, B. F.,, and J. A. Moody. 1991. Human infections associated with Bordetella bronchiseptica. Clin. Microbiol. Rev. 4:243255.
105. World Health Organization. 1999. Pertussis vaccines: WHO position paper. WHO Wkly. Epidemiol. Rec. 18:136143.
106. World Health Organization. 2006. WHO vaccine preventable diseases monitoring system: 2006 global summary. World Health Organization, Geneva, Switzerland.
107. Wortis, N.,, P. M. Strebel,, M. Wharton,, B. Bardenheier,, and I. R. Hardy. 1996. Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 97:607612.
108. Yih, W. K.,, E. A. Silva,, J. Ida,, N. Harrington,, S. M. Lett,, and H. George. 1999. Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg. Infect. Dis. 5:441443.
109. Yih, W. K.,, S. M. Lett,, F. N. des Vignes,, K. M. Garrison,, P. L. Sipe,, and C. D. Marchant. 2000. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998. J. Infect. Dis. 182:14091416.


Generic image for table
Table 1.

Recommended antimicrobial treatment and postexposure prophylaxis for pertussis by age group

Citation: Tiwari T. 2008. Pertussis, p 257-275. In Scheld W, Hammer S, Hughes J (ed), Emerging Infections 8. ASM Press, Washington, DC. doi: 10.1128/9781555815592.ch13

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error